Clinical trial of nedaplatin injection combined with radiotherapy in the treatment of esophageal cancer
10.13699/j.cnki.1001-6821.2017.21.007
- VernacularTitle:奈达铂注射剂联合放疗治疗食管癌的临床研究
- Author:
BAERXIAGULI·Zabihula
1
;
MOKEDAISI·Yiliyasi
;
YISIKANDAER·Abulimiti
Author Information
1. 新疆医科大学附属肿瘤医院胸腹放疗科
- Keywords:
nedaplatin injection;
radiotherapy;
esophageal cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(21):2114-2116
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of nedaplatin injection combined with radiotherapy in the treatment of esophageal cancer.Methods Fifty-six patients with esophageal cancer were randomly divided into control group and treatment group with 28 cases per group.Control group was treated with radiotherapy alone,5 times a week.On the basis of control group,treatment group was given 90 mg · m-2 nedaplatin,intravenous drip for more than 2 h on the first day,with 3 weeks per cycle.Two groups were treated for 6 weeks.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control group were 82.14％ (23 cases/28 cases) and 57.14％ (16 cases/28 cases) with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were based on radiation esophagitis,nausea and vomiting,elevated alanine aminotransferase,thrombocytopenia,reducedhemoglobin and leukocyte levels.The incidences of adverse drug reactions in treatment and control groups were compared:radiation esophagitis were 21.43％ and 17.86％,nausea and vomiting were 32.14％ and 21.43％,elevated alanine aminotransferase were 10.71％ and 7.14％,thrombocytopenia were 21.43％ and 10.71％,reduced hemoglobin level were 14.29％ and 7.14％,reduced leukocyte level were 21.43％ and 17.86％,the differences were not statistically significant (all P ＞ 0.05).Conclusion Nedaplatin injection combined with radiotherapy has a definitive clinical efficacy in the treatment of esophageal cancer,without increasing the incidence of adverse drug reactions.
